Navigation Links
New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients
Date:3/9/2009

New York, NYMarch 9, 2009InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced a new study published in the peer-reviewed Journal of Human Hypertension. The advance online publication of the study is now available on the journal's website. The study will also be published in the May issue of the journal, Volume 23, Issue 5. It demonstrates use of RESPeRATEthe only medical device cleared by the FDA and CE-approved for the adjunctive treatment of hypertensionfor 15 minutes a day significantly lowered blood pressure in non-insulin dependent diabetics. This study reinforces nine previous studies that validate the efficacy of the device.

The randomized, controlled trial of 66 non-insulin dependent (Type II) diabetic patients with uncontrolled blood pressure was conducted by Moshe H. Schein, MBChB, M.S., Hadassah-Hebrew University Medical Center.

Despite the fact that 82 percent of the study population was already taking antihypertensive medication before the start of the trial, baseline systolic blood pressure levels remained high while diastolic levels were controlled. Study participants using device-guided breathing with RESPeRATE at home for eight weeks experienced a significant reduction in office systolic blood pressure (mean+SE) -10.0+1.8 mm Hg (p< 0.0001), but similar results were not seen in the control group +1.6+2.1 mm Hg (p>0.4). A full 88 percent of patients using RESPeRATE experienced a significant blood pressure reduction, in contrast to only 45 percent of the control group.

"A high percentage of diabetic complications can be attributed to hypertension. However data shows that only 20 percent of diabetic patients reach the recommended target blood pressure," said Dr. Schein, the lead investigator. "It is therefore encouraging that an effective non-drug therapy can help this population improve its blood pressure control. The compliance with treatment in the study was high and in addition the patients reported feeling more relaxed after the device-guided breathing."

Hypertension is a common co-morbidity in patients with diabetes mellitus and is an important factor in the increased risk of coronary heart disease and stroke in diabetics. Lowering blood pressure in the diabetic population is crucially important, yet difficult to achieve. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends aggressive hypertension treatment for diabetics, including pharmacological and non-pharmacological interventions, in order to reduce blood pressure below 130/80 mm Hg. Despite this aggressive approach, only 44.3 percent achieve blood pressure goals below 140/90 mm Hg and only 20.4 percent reach the recommended target of below 130/80 mm Hg.

"This new study provides a clear demonstration of the non-drug benefits of RESPeRATE among the high-risk diabetes population," said Erez Gavish, president and CEO of InterCure. "Diabetics facing a daily regimen of monitoring, insulin injections and prescription medication for secondary conditions have long supported the truly natural hypertension treatment RESPeRATE provides. Diabetic nurse educators and clinicians across the country now have even more reason to discuss RESPeRATE as a viable option among this hard-to-control, high-risk patient population."


'/>"/>

Contact: Lisa Mokaba
intercure@schwartz-pr.com
781-684-0770
Schwartz Communications
Source:Eurekalert

Related medicine news :

1. Published Data Confirms First 3D Ultrasound for Breast Cancer Treatment Planning Helps Radiation Oncologists Better Define Treatment Region
2. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
3. Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS
4. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
5. Major study on DiagnoCures GCC biomarker published in Jama
6. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
7. Complete Genomes of All Known Human Rhinoviruses are Published
8. Published Study Shows Brain Exercises Improve Memory and Attention - And People Notice
9. New guidelines for prescribing opioid pain drugs published
10. New Guidelines for Prescribing Opioid Pain Drugs Published
11. Emergency Treatment Strategies, Better Communication Among Health Care Workers Reduce Heart Attack Patient Deaths by 19 Percent, Says AHJ Published Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... The V ... announce its Not a Moment to Lose fundraising campaign. As the V Foundation’s ... to declaring victory over cancer. The campaign aims to raise $200 million by ...
(Date:12/6/2016)... ... 2016 , ... GrekTek LLC, ( http://www.grektek.com ) an mHealth ... ) for the HealthyWatch, a new device to help patients manage their health ... while sharing these events with caregivers in real time. , “One ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... to understand the scope of their EHS regulatory obligations and rapidly collect, share, ...
(Date:12/5/2016)... ... December 05, 2016 , ... What: Shriners Hospitals for Children, with the help ... patients – using a video monitor and web-enabled camera. Santa visits with children through ... into a Christmas Wonderland, which is where the video connection to the North Pole ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Dec. 5, 2016  Sharn Anesthesia Inc. announced today ... and distribution partner for Salter Labs.  The company also ... in recognition of outstanding sales performance. Salter ... and anesthesia care, including the market gold standard ECO ... master distributor of the Parker Flex-Tip® Endotracheal Tube, which ...
(Date:12/5/2016)... , Dec. 5, 2016   BIOTRONIK today ... study. The study evaluates the safety and feasibility of ... an office setting. BioMonitor 2 is an ... that is placed underneath a patient,s skin to help ... (fainting). Atrial fibrillation is a leading cause of stroke ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sanovas, ... technology accelerator, announced today the launch of its wholly owned ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO ... ... There ...
Breaking Medicine Technology: